-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ExD0eqCo0yIJJcIskDwh03hxEF7ZQ7Zns+Eu42+4hn8y5PXGtm7tt4aHKa6h4KJ+ dU6z1LMcrmW+TZ3MhSjkhA== 0001079973-06-000422.txt : 20061106 0001079973-06-000422.hdr.sgml : 20061106 20060630164701 ACCESSION NUMBER: 0001079973-06-000422 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: CA FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1725 GILLESPIE WAY STREET 2: STE H CITY: EL CAJON STATE: CA ZIP: 92020 BUSINESS PHONE: 6195968600 MAIL ADDRESS: STREET 1: 1725 GILLESPIE WAY STREET 2: SUITE H CITY: EL CAJON STATE: CA ZIP: 92020 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 CORRESP 1 filename1.txt Correspondence Pure Bioscience 1725 Gillespie Way El Cajon, CA 92020 June 30, 2006 BY FACSIMILE to 202 772 9217 AND EDGAR - ---------------------- Ms. Jennifer Hardy Mr. Andrew Schoeffler Securities And Exchange Commission 100 F. Street N.E. Mail Stop 7010 Washington, D.C. 20549 Re: Pure Bioscience Registration Statement on Form SB-2 File No. 333-133500 Dear Ms Hardy and Mr. Schoeffler: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Pure Bioscience (the "Company") hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that the Registration Statement may become effective at 4:00 p.m. Eastern Time on Friday, July 7, 2006, or at such later time as the Company may request by telephone to the Commission. The Company hereby confirms that it is aware of its obligations under the Securities Act and the Securities Exchange Act of 1934, as amended, with respect to the registration of securities specified in the above-referenced Registration Statement. Further, the Company acknowledges that: o should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; o the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and o the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you or any member of the Staff has comments or questions, please contact our counsel Dennis Brovarone, at 303 466 4092. Very truly yours, Pure Bioscience By /s/ Michael L. Krall ------------------------------ Michael L. Krall, President cc: Dennis Brovarone, Esq. -----END PRIVACY-ENHANCED MESSAGE-----